摘要
目的本文应用Meta分析的方法评价白三烯拮抗剂治疗前后对血清白细胞介素5(IL-5)的影响,系统评价使用白三烯受体拮抗剂对哮喘治疗前后IL-5变化,探讨IL-5与白三烯受体拮抗剂关系以及其在哮喘中的免疫学作用机制。方法采用Meta分析方法对国内相关文献进行定量综合分析。结果共检索到白三烯拮抗剂治疗哮喘相关文献50篇,从中筛选出符合Meta分析要求的白三烯治疗哮喘前后自身血清IL-5水平对比测定的文献3篇。均符合单个对照研究文献IIa级。共纳入86例患者,Meta分析结果显示经白三烯拮抗剂治疗自身对照血清IL-5治疗前后有显著差异,Z=7.23,(P<0.00001),具有统计学意义(效应值SMD=1.21,95%CI:0.88～1.54)。结论本次所纳入的文献数据综合Meta分析发现白三烯拮抗剂对哮喘患者血清IL-5的下降有显著疗效(白三烯受体拮抗剂可降低哮喘患者血清IL-5水平1.21倍)。
Objective To study the relationship of cysteinyl leukotrienes receptor（LTs）antagonist on serum level of IL-5 and investigate the effects of antagonist of LTs in asthma.Methods A Meta analysis with date collected from domestic reports concerning antagonist of LTs was made to study the different level of serum IL-5 before and after treatment with antagonist of LTs.Results The level of serum IL-5 in the patients treated with antagonist of LTs were 1.21 times lower than before treatment（z=7.23,p0.00001,95%CI：0.88～1.54）.There is significant difference between before and after treatment with antagonist of LTs.Conclusion The antagonist of LTs may effectively inhibit the serum level of inflammational cytokins,such as IL-5 in asthma patient.
出处
《中外医疗》
2011年第32期88-90,共3页
China & Foreign Medical Treatment
